Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones \[i.e., peroxisome proliferator activated receptor-gamma, PPARγ agents\])~* male or a female of non-childbearing potential. Women must be postmenopausal or premenopausal and documented surgically sterilized~* A body mass index (BMI) that is \> 20 and ≤ 40 kg/m2~Exclusion Criteria:~* History of type 1 diabetes or assessed by the investigator as possibly having type 1 diabetes~* History of ketoacidosis; clinically unstable or rapidly progressive diabetic retinopathy, nephropathy, neuropathy~* Treatment for diabetes within 3 months of study participation with combination anti-hyperglycemic therapy, insulin or thiazolidinediones (e.g., rosiglitazone or pioglitazone)~* oral corticosteroid medications within 2 weeks prior to study participation, or requires digoxin, warfarin, warfarin-like anticoagulants, theophylline, anti-dysrhythmic or anti-seizure medications, immunosuppressants, or anti-neoplastic agents, or herbal remedies~* History of acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)~* History of gastrointestinal problems or disorders or extensive bowel or gastric surgery~* History of significant or unstable cardiovascular disease~* History of neoplastic disease~* History of hepatic disease~* History of seizures, epilepsy or other neurologic disease~* History of myelodysplastic or pre-leukemic disorders or other severe hematological disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-0893 (40 mg) (Type: EXPERIMENTAL): MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
- MK-0893 (120 mg) (Type: EXPERIMENTAL): MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
- Metformin (2000 mg) (Type: ACTIVE_COMPARATOR): Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching the MK-0893 and placebo tablets matching metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).